Full text is available at the source.
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist
Oral Semaglutide: Review of the First Pill That Mimics a Blood Sugar-Regulating Hormone
AI simplified
Abstract
The oral formulation of semaglutide demonstrates similar efficacy to injectable GLP-1 receptor agonists in lowering hemoglobin A1c and facilitating weight loss.
- Glucagon-like peptide 1 receptor agonists are effective in reducing hemoglobin A1c and promoting weight loss.
- Four GLP-1 receptor agonists also show potential cardioprotective effects.
- Subcutaneous administration has limited the use of these agents.
- A new oral formulation of semaglutide uses sodium N-[8-(2-hydroxybenzoyl) amino caprylate] to enhance absorption.
- The oral semaglutide was evaluated in PIONEER trials, showing comparable effectiveness to existing injectable options.
- The PIONEER 6 trial indicates potential benefits on cardiovascular mortality, pending further confirmation from the SOUL trial.
AI simplified